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Immediate Reproducibility of Clinical and Nonclinical 
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JEFFREY M. BAERMAN, MD, and RYSZARD B. KROL, MD 
This prospective study assessed the immediate re- 
producibility of clinical and nonclinical forms of ven- 
tricular tachycardia (VT) induced by programmed 
ventricular stimulation. Twenty-three clinical VTs 
were unimorphic and previously documented and 22 
nonclinical VTs (17 polymorphic and 5 unimorphic) 
were induced in patients with either no documented 
or suspected history of VT, or documented VT that 
had a configuration different from that of the in- 
duced VT. The stimulation, protocol included 1 to 3 
ventricular extrastimuli, 2 drive cycle lengths, and 2 
right ventricular stimulation sites. Each VT was in- 
duced on the first attempt, then the stimulation pro- 
tocol was repeated twice in the drug-free state. Af- 
ter the first VT induction, 21 of 23 clinical VTs 
(91%) and 17 of 22 nonclinical VTs (77%) were 
reinduced on the second attempt. After 2 VT induc- 
tions, 21 of 21 clinical VTs (100%) and 15 of 17 
nonclinical VTs (88%) were reinduced on the third 
attempt. The reinduction rates of the clinical and 
nonclinical Ws were not significantly different. 
Among the clinical VTs, the reproducibility of the in- 
duction technique was 81% after 1 induction and 
88% after 2 inductions with the same technique. 
These results imply that (1) acute drug testing can 
be reliably performed after 2 inductions but not 1 in- 
duction of clinical VT; (2) reproducibility is not help- 
ful in determining whether an induced VT is clinical 
or nonclinical; and (3) changes in induction tech- 
nique during drug testing should be interpreted with 
caution because changes may occur in the absence 
of drugs. (Am J Cardiol 1986;58:279-282) 
R eliable assessment of drug efficacy during acute 
electropharmacologic testing depends on the immedi- 
ate reproducibility of.ventricular tachycardia (VT] in- 
duced by programmed ventricular stimulation. It has 
been suggested that an increase in the number of ex- 
trastimuli required to induce VT after administration 
of a drug may predict a good clinical response to that 
drug.lJ However, no studies have critically analyzed 
the immediate reproducibility of either VT induction 
or the number of extrastimuli required to induce VT. 
Programmed ventricular stimulation may induce 
not only clinical forms of VT, but also nonclinical 
forms3v4 In a patient with suspected but undocument- 
ed VT, it may be unclear whether the VT induced by 
programmed ventricular stimulation is clinically im- 
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portant. It has been suggested that the ability to repro- 
ducibly induce a particular form of VT implies that the 
VT is clinically significant5 However, no studies have 
compared the immediate reproducibility of clinical 
and nonclinical forms of VT. 
This prospective study was designed to answer 3 
questions: If a particular form of VT is inducible on 2 
attempts, does this guarantee inducibility on a third 
attempt? When VT can be induced on 3 attempts, what 
is the reproducibility of the induction technique that 
induced VT on the first attempt? Is there a difference 
in reproducibility of clinical and nonclinical forms of 
VT induced by programmed ventricular stimulation? 
Methods 
Study participants consisted of 42 consecutive pa- 
tients undergoing electrophysiologic study and meet- 
ing the entry criteria: VT was inducible by pro- 
grammed ventricular stimulation, VT did not require 
direct-current countershock to terminate, and the pa- 
tient had either a history of sustained unimorphic VT 
documented on a 12-lead electrocardiogram or no his- 
tory of documented or suspected VT. Each patient 
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with no history of VT had at least one %-hour ambula- 
tory electrocardiographic recording demonstrating ab- 
sence of more than 3 consecutive ventricular prema- 
ture complexes. Induced VT was categorized as 
clinical when it was identical to the patient’s spontane- 
ous VT, as documented by a 12-lead electrocardio- 
graphic recording. Induced VT was categorized as 
nonclinical if it was induced in patients with no history 
of documented or suspected VT or if it was induced in 
a patient with documented VT but had a different 
configuration than the documented VT. Sustained VT 
was defined as VT lasting at least 30 seconds. Nonsus- 
tained VT was defined as VT 6 beats to 30 seconds in 
duration. 
Patient characteristics: Patient characteristics are 
described in Table I. In 3 patients, both clinical and 
nonclinical forms of VT were induced. 
Characteristics of induced ventricular tachycar- 
dia: Twenty-three VTs were clinical and 22 were non- 
clinical. VT characteristics are listed in Table II. 
The 23 clinical VTs were induced in patients who 
had a documented history of sustained unimorphic VT 
and who were undergoing electropharmacologic test- 
ing. Of the 22 nonclinical VTs, the 17 that were poly- 
morphic and nonsustained were induced in patients 
TABLE I Patient Characteristics 
Clinical VT Nonclinical VT 
No. of pts 
Males/females 
Age (yr) (mean f SD) 
Heart disease 
Coronary artery disease 
Dilated cardiomyopathy 









* Three patients also had inducible nonclinical VT. 
SD = standard deviation; VT = ventricular tachycardia. 
TABLE II Characteristics of Induced Ventricular Tachycardias 
Clinical VTs Nonclinical VTs 
No. of pts 23 22 
Configuration 
Right bundle branch block 14 3 
Left bundle branch block 9 2 
Polymorphic 0 17 
Duration 
Nonsustained (6 beats-30 set) 1 22 
Sustained (>30 set) 22 0 
Cycle length (ms) (mean f SD) 312 f 60 212 f 56’ 
No. of extrastimuli required to 
induce VT on first attempt 
1 5 0 
2 13 11 
3 5 11 
Right ventricular induction site 
Apex 21 16 
Outflow tract or septum 2 6 
* p <O.OOi vs clinical VTs. 
SD = standard deviation; VT = ventricular tachycardia. 
with sick sinus syndrome, atrioventricular conduction 
disturbances, carotid hypersensitivity, paroxysmal su- 
praventricular tachycardia or unexplained syncope 
undergoing programmed ventricular stimulation in 
the course of a complete electrophysiologic study. 
Nonsustained polymorphic VT induced in patients 
with unexplained syncope has been shown not to be of 
clinical significance. 4-6,7 The 5 nonclinical VTs that 
were unimorphic were induced in patients with a his- 
tory of sustained unimorphic VT, which had a configu- 
ration different from that of the induced VT. 
Programmed ventricular stimulation protocol: 
Patients were studied in the fasting, unsedated state 
after they gave informed consent. Antiarrhythmic 
drug therapy was discontinued at least 4 half-lives be- 
fore electrophysiologic study. Two No. 6Fr quadripo- 
lar electrode catheters were inserted percutaneously 
into a femoral vein and positioned against the right 
ventricular apex and either the right ventricular out- 
flow tract or septum. A programmable stimulator 
(Bloom Associates, Ltd.] was used to deliver stimuli at 
twice diastolic threshold and 2 ms in duration. Leads 
VI, I and III and intracardiac electrograms were dis- 
played on an oscilloscope and recorded on an Elec- 
tronics for Medicine VR-16 recorder at a paper speed 
of 25 mm/s. When unimorphic VT was induced, a l2- 
lead electrocardiogram was recorded. 
Programmed ventricular stimulation was per- 
formed with single and double extrastimuli using 6- to 
8-beat drive trains, 2 drive cycle lengths (600 or 500 ms 
and 400 ms), and 10-ms decrements, first at the apex 
and then at the second right ventricular site. If an 
endpoint of the stimulation protocol was not reached, 
triple extrastimuli were then introduced, first at the 
apex and then at the second right ventricular site. 
In patients who had a history of documented uni- 
morphic VT, the endpoint of the stimulation protocol 
was induction of clinical VT. In patients with no histo- 
ry of documented or suspected VT, the endpoint was 
induction of any form of VT. If VT or ventricular fibril- 
lation requiring direct-current countershock was in- 
duced, the patient was excluded from the study. 
In each patient, VT was induced on the first attempt 
at programmed stimulation. The programmed ventric- 
ular stimulation protocol was immediately repeated 
twice after the first induction of VT. On the second and 
third attempts, programmed ventricular stimulation 
was initiated at the same site and basic drive cycle 
length used to induce VT on the first attempt. If VT 
was not induced, the remainder of the stimulation pro- 
tocol was then carried out. 
Statistical analysis was performed with a Student t 
test and chi-square analysis. A p value CO.05 was con- 
sidered statistically significant. 
Results 
Reproducibility after one induction of ventricular 
tachycardia: After 1 induction of VT, 21 of 23 clinical 
VTs (91%) were induced on the second attempt. In 2 
patients, both of whom had coronary artery disease, no 
VT was induced when the entire programmed ventric- 
ular stimulation protocol was repeated. One of the 
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nonreproducible VTs was induced by double extra- 
stimuli and 1 by triple extrastimuli on the initial 
attempt. 
After 1 induction of VT, 17 of 22 nonclinical VTs 
(77%) were induced on the second attempt. In 5 pa- 
tients who originally had inducible nonclinical VT, no 
VT was induced when the entire stimulation protocol 
was repeated; 4 of these patients had coronary artery 
disease and 1 had dilated cardiomyopathy. 
The 77% reinduction rate for the nonclinical VTs 
was not significantly different from the 91% reinduc- 
tion rate for the clinical VTs. 
Reproducibility after two inductions of ventricu- 
lar tacbycardia: Among the 21 clinical VTs that were 
induced twice, all 21 were again inducible on the third 
attempt. 
Among the 17 nonclinical VTs that were induced 
twice, 15 (88%) were inducible on the third attempt. 
This 88% reinduction rate for nonclinical VTs was not 
significantly different from the 100% reinduction rate 
for clinical VTs. 
Reproducibility of induction technique: Among 
the 21 clinical VTs that were reproducibly induced on 
the first 2 attempts, 17 of 21(81%) were induced by the 
same number of extrastimuli on both occasions. One 
clinical VT required fewer extrastimuli to induce the 
second time, and 3 required more extrastimuli. All VTs 
were reinduced at the original stimulation site. Among 
17 clinical VTs induced on 3 occasions that were in- 
duced by the same technique on the first 2 attempts, 
the same technique induced VT on the third attempt in 
15 of 17 cases (88%). One clinical VT required fewer 
extrastimuli to induce the third time and 1 required 
more extrastimuli. 
Among the 17 nonclinical VTs that were reproduc- 
ibly induced on the first 2 attempts, 16 of 17 (94%] were 
induced by the same number of extrastimuli on both 
attempts. Among 14 nonclinical VTs induced on 3 oc- 
casions that were induced by the same technique on 
the first 2 attempts, the same technique induced VT on 
the third attempt in 12 of 14 cases (86%]. 
Discussion 
No studies to date have addressed the question of 
how many times a clinical VT must be induced in the 
control state before the results of acute electropharma- 
cologic testing can be meaningfully interpreted. The 
results of the present study indicate that acute electro- 
pharmacologic testing can be reliably performed after 
2 inductions of VT, but not after 1. Approximately 10% 
of clinical VTs that were induced once were not induc- 
ible on a second attempt at programmed ventricular 
stimulation. However, clinical VTs induced twice 
were always inducible a third time. Therefore, 2 in- 
ductions of a given form of clinical VT in the control 
state appear adequate to ensure that the absence of 
inducible VT during acute drug testing is due to a drug 
effect and not random noninducibility. 
Although 2 inductions of a clinical VT predicted a 
high degree of reproducibility in inducing the VT on a 
third occasion, the reproducibility of the specific in- 
duction technique was not as high. Even when VT is 
induced by the same step in the stimulation protocol 
on 2 consecutive occasions, there is approximately a 
10% chance that VT induction will require fewer or 
more extrastimuli on the third attempt. 
This observation has 2 important implications re- 
garding electropharmacologic testing. First, because 
even in the control state induction of VT on a third 
attempt may require more extrastimuli than required 
on the first 2 attempts, during drug testing it may not be 
adequate to stimulate only up to the step in the protocol 
that induced VT in the control state; even if VT was 
induced on 2 occasions in the control state with 1 or 2 
extrastimuli, the drug testing protocol should include 3 
extrastimuli to ensure that an apparent drug response 
is not due to random change in the induction tech- 
nique. Second, because the induction technique may 
change in the absence of drugs, a change in the num- 
ber of extrastimuli required to induce VT during drug 
testing must be interpreted with caution. A decrease in 
the number of extrastimuli required to induce VT dur- 
ing drug testing has been suggested as indicating a 
proarrhythmic effect.8 Furthermore, an increase in the 
number of extrastimuli required to induce VT during 
drug testing has been suggested as indicating a benefi- 
cial drug effect .lr2 However, the results of the present 
study suggest that after 2 inductions of VT by the same 
technique in the control state, there is at least a 10% 
chance that a change in the number of extrastimuli 
required to induce VT during drug testing is a random 
change not due to the drug. If VT is induced only once 
in the control state, this probability increases to ap- 
proximately 20%. 
In patients in whom documentation of the sponta- 
neous VT is adequate, VT induced by programmed 
ventricular stimulation can be clearly identified as be- 
ing clinical or nonclinical. However, in patients with 
inadequately documented VT or suspected but undoc- 
umented VT, the clinical significance of an induced 
VT may be unclear. It has been suggested that the 
ability to reproducibly induce a particular form of VT 
may indicate that the VT is clinically significant.5 
However, the results of the present study demonstrate 
that reproducibility of an induced VT does not distin- 
guish clinical from nonclinical tachycardia. Although 
reproducibility of nonclinical VTs tended to be lower 
than that of clinical VTs, there was no significant dif- 
ference between the 2. Therefore, the ability to repro- 
ducibly induce a VT of unclear significance should not 
be considered evidence that the VT is clinical. 
All of the clinical VTs in this study were unimor- 
phic. Although sustained polymorphic VT may, at 
times, be a clinical arrhythmia, as in patients who have 
had an out-of-hospital cardiac arrest, the reproducibil- 
ity of this type of VT was not assessed in this study for 2 
reasons: repeated induction of sustained polymorphic 
VT may have necessitated multiple direct-current 
countershocks, and even in patients with out-of-hospi- 
tal cardiac arrest, the clinical significance of sustained 
polymorphic VT may be uncleare Therefore, the con- 
clusions of this study regarding reproducibility of clin- 
ical VTs are applicable only to sustained unimorphic 
VT. 
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The nonclinical VTs in this study included both 
nonsustained polymorphic and sustained unimorphic 
tachycardias. The polymorphic VTs were considered 
nonclinical because they were induced in patients 
with no documented history of VT or in patients with a 
history of only unimorphic VT. The nonclinical uni- 
morphic VTs were induced in patients with a history of 
documented unimorphic VT. Patients with a docu- 
mented history of unimorphic VT often have multiple 
morphologic patterns of unimorphic VT and an in- 
duced unimorphic VT should therefore not be catego- 
rized as nonclinical unless every spontaneous episode 
has been documented.g This was the case in the pa- 
tients in this study. 
In conclusion, inability to induce VT during’ acute 
electropharmacologic testing can be considered a val- 
id response if the VT was induced at least twice before 
the drug was administered. However, the induction 
technique may be variable even in the absence of 
drugs; therefore, the apparent effects of a drug on the 
number of extrastimuli required to induce VT must be 
interpreted with caution. Finally, reproducibility of an 
induced VT is not a valid criterion by which the VT 
can be judged to be clinical or nonclinical. 
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